---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-004759"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:48:28.005389+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort

## Summary
- Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.
- No dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent reactions in fourth cohort (5 patients).
- To date, 15 patients treated; pathological complete response (100% clearance) seen in 4 of 9 cSCC patients from prior cohorts.
- Enrollment in final cohort expected to complete in Q3 2025.
- PH-762 is an intratumoral siRNA targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.

## SEC filing metadata
- accession: 0001683168-25-004759
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825004759/0001683168-25-004759-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825004759/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-004759
- JSON: https://secwatch.observer/filing/0001683168-25-004759.json
- Plain text: https://secwatch.observer/filing/0001683168-25-004759.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.